FMP

FMP

Enter

GOSS - Gossamer Bio, I...

photo-url-https://images.financialmodelingprep.com/symbol/GOSS.png

Gossamer Bio, Inc.

GOSS

NASDAQ

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

0.874 USD

-0.0043 (-0.492%)

About

ceo

Mr. Faheem Hasnain

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system ...

CIK

0001728117

ISIN

US38341P1021

CUSIP

38341P102

Address

3013 Science Park Road

Phone

858 684 1300

Country

US

Employee

135

IPO Date

Feb 8, 2019

GOSS Financial Summary

CIK

0001728117

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

38341P102

ISIN

US38341P1021

Country

US

Price

0.87

Beta

1.96

Volume Avg.

834.31k

Market Cap

197.65M

Shares

-

52-Week

0.494-1.6

DCF

-1.18

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.6

P/B

-

Website

https://www.gossamerbio.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest GOSS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep